Prestige Consumer Healthcare Inc PBH
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PBH is a good fit for your portfolio.
News
-
Fanatics Betting and Gaming Closes its Acquisition of the US Businesses of PointsBet
-
Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag
-
Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results
-
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene
Trading Information
- Previous Close Price
- $69.77
- Day Range
- $70.36–71.82
- 52-Week Range
- $54.40–75.32
- Bid/Ask
- $71.25 / $71.32
- Market Cap
- $3.54 Bil
- Volume/Avg
- 83,235 / 246,950
Key Statistics
- Price/Earnings (Normalized)
- 15.98
- Price/Sales
- 2.99
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.72%
Company Profile
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 560
- Website
- https://www.prestigebrands.com
Competitors
Valuation
|
Metric
|
PBH
|
PG
|
HLN
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.98 | 24.58 | 18.19 |
Price/Book Value | 2.11 | 7.69 | 1.82 |
Price/Sales | 2.99 | 4.72 | 2.76 |
Price/Cash Flow | 11.87 | 19.58 | 17.28 |
Price/Earnings
PBH
PG
HLN
Financial Strength
|
Metric
|
PBH
|
PG
|
HLN
|
|---|---|---|---|
Quick Ratio | 1.87 | 0.40 | 0.63 |
Current Ratio | 3.09 | 0.64 | 1.04 |
Interest Coverage | −0.28 | 20.66 | 4.87 |
Quick Ratio
PBH
PG
HLN
Profitability
|
Metric
|
PBH
|
PG
|
HLN
|
|---|---|---|---|
Return on Assets (Normalized) | 8.80% | 13.82% | 4.68% |
Return on Equity (Normalized) | 19.44% | 35.61% | 9.76% |
Return on Invested Capital (Normalized) | 12.65% | 20.62% | 7.06% |
Return on Assets
PBH
PG
HLN
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Hqbfrtkpr | Jvc | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Zbprzryw | Ttcspcv | $68.4 Bil | |
HLN
| Haleon PLC ADR | Hmxsdbvr | Mldgj | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Bjgvdqt | Mdyb | $14.5 Bil | |
VTRS
| Viatris Inc | Sfjlnqgmb | Btwc | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Lsjmybdb | Pxqyk | $12.0 Bil | |
CTLT
| Catalent Inc | Vtkbtsfp | Czrnln | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Jszrmhhyd | Wdlw | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Tkmcfydc | Jgy | $3.6 Bil |